Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
Prospective Phase II Clinical Trial of Myeloablative Conditioning Regimen With Fludarabine and Busulfan Plus 400 cGy Total Body Irradiation for Hematologic Malignancies
研究概览
详细说明
Conventional allogeneic hematopoietic cell transplantation (HCT) for patients with hematological malignancies involves conditioning with high doses of systemic chemo/radiation therapy such as cyclophosphamide (CY) plus 1200 or 1000 cGy total body irradiation (TBI; CY/TBI) or busulfan (Bu) / CY (BuCy). Unfortunately, such regimens have been associated with significant toxicities, limiting their use to otherwise healthy, relatively young patients.
Recently, Fludarabine plus 4 day dose of busulfan (FluBu4) containing myeloablative regimen has been introduced successfully without increasing transplant-related mortality (TRM). To improve transplant outcomes without increasing the risk of recurrence, Russell et al introduced 400cGy of TBI with antithymocyte (ATG, 4.5mg/Kg) into FluBu4 regimen with successful outcomes.
研究类型
注册 (预期的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Dong Hwan Kim
- 电话号码:+82-2-3410-1768
- 邮箱:drkiim@medimail.co.kr
学习地点
-
-
-
Seoul、大韩民国、135-710
- 招聘中
- Dong Hwan Kim
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- At least 15 years old and not more than 65 years old.
- ECOG performance status 0-2.
- Patients with AML or MDS with intermediate/unfavorable cytogenetics.
- Patients with ALL and CML ineligible for Cy/TBI conditioning.
- Patients with NHL or HD eligible to myeloablative HCT.
- Patients receiving unrelated BMT for AML, MDS, ALL, CML, NHL or HD.
- Consent form signed and dated prior to study specific procedures.
- Subject able to comply with the scheduled follow-up and with the management of toxicities.
Exclusion Criteria:
-
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Regimen
Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
|
Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
无进展生存期
大体时间:一年
|
一年
|
次要结果测量
结果测量 |
大体时间 |
---|---|
relapse of primary disease, overall survival, and occurrence of acute/chronic GVHD
大体时间:one year
|
one year
|
合作者和调查者
调查人员
- 研究主任:Dong Hwan Kim、Samsung Medical Center
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
fludarabine phosphate, busulfan的临床试验
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Department of Medical Research, Lower Myanmar撤销无并发症的恶性疟疾 | 青蒿素抗性
-
Medicines for Malaria VentureNucleus Network Ltd; Southern Star Research Pty Ltd.完全的
-
Mateon Therapeutics完全的
-
Muhimbili University of Health and Allied SciencesKarolinska Institutet; Uppsala University; The University of Western Australia完全的
-
Ciceri Fabio完全的骨髓增生异常综合征 | 真菌感染 | 移植物抗宿主病 | 白血病,急性 | 移植相关血液系统恶性肿瘤意大利